BIOMARIN PHARMACEUTICAL INC Amortization of Debt Issuance Costs and Discounts
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Amortization of Debt Issuance Costs and Discounts of $27.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $21.83M, a 3206.97% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $6.09M, a 822.12% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $653.00K, a 1.06% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $649.00K, a 9.61% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for fiscal 2025 was $2.62M, a 21.94% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for fiscal 2024 was $3.36M, a 19.79% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for fiscal 2023 was $4.19M, a 1.72% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC amortization of debt issuance costs and discounts for fiscal 2022 was $4.12M, a 0.70% decline from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $27.91M 10-Q · filed 2026-08-06 | $28.57M derived: sum of 3 quarters · filed 2026-08-06 | $29.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.09M 10-Q · filed 2026-05-05 | $6.74M derived: sum of 2 quarters · filed 2026-05-05 | $7.39M derived: sum of 3 quarters · filed 2026-05-05 | $8.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $653.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.30M derived: sum of 2 quarters · filed 2026-02-26 | $1.96M derived: sum of 3 quarters · filed 2026-08-06 | $2.62M 10-K · filed 2026-02-26 |
| 2025-09-30 | $649.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.31M derived: sum of 2 quarters · filed 2026-08-06 | $1.97M 10-Q · filed 2025-10-28 | $2.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $660.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.32M 10-Q · filed 2026-08-06 | $1.98M derived: sum of 3 quarters · filed 2026-08-06 | $2.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $660.00K 10-Q · filed 2026-05-05 | $1.32M derived: sum of 2 quarters · filed 2026-05-05 | $2.04M derived: sum of 3 quarters · filed 2026-05-05 | $3.03M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $660.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.38M derived: sum of 2 quarters · filed 2026-02-26 | $2.37M derived: sum of 3 quarters · filed 2026-02-26 | $3.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | $718.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.71M derived: sum of 2 quarters · filed 2025-10-28 | $2.70M 10-Q · filed 2025-10-28 | $3.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $991.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.98M 10-Q · filed 2025-08-05 | $2.97M derived: sum of 3 quarters · filed 2026-02-26 | $4.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $990.00K 10-Q · filed 2025-05-02 | $1.98M derived: sum of 2 quarters · filed 2026-02-26 | $3.12M derived: sum of 3 quarters · filed 2026-02-26 | $4.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $990.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.13M derived: sum of 2 quarters · filed 2026-02-26 | $3.16M derived: sum of 3 quarters · filed 2026-02-26 | $4.19M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.17M derived: sum of 2 quarters · filed 2024-10-31 | $3.20M 10-Q · filed 2024-10-31 | $4.23M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $2.06M 10-Q · filed 2024-08-05 | $3.09M derived: sum of 3 quarters · filed 2025-02-24 | $4.11M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $1.03M 10-Q · filed 2024-04-26 | $2.06M derived: sum of 2 quarters · filed 2025-02-24 | $3.08M derived: sum of 3 quarters · filed 2025-02-24 | $4.11M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $2.06M derived: sum of 2 quarters · filed 2025-02-24 | $3.08M derived: sum of 3 quarters · filed 2025-02-24 | $4.12M 10-K · filed 2025-02-24 |
| 2022-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.06M derived: sum of 2 quarters · filed 2023-11-02 | $3.09M 10-Q · filed 2023-11-02 | $4.12M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $2.06M 10-Q · filed 2023-08-02 | $3.09M derived: sum of 3 quarters · filed 2024-02-26 | $4.13M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $1.03M 10-Q · filed 2023-04-28 | $2.06M derived: sum of 2 quarters · filed 2024-02-26 | $3.10M derived: sum of 3 quarters · filed 2024-02-26 | $4.14M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $2.06M derived: sum of 2 quarters · filed 2024-02-26 | $3.10M derived: sum of 3 quarters · filed 2024-02-26 | $4.15M 10-K · filed 2024-02-26 |
| 2021-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $2.07M derived: sum of 2 quarters · filed 2022-10-28 | $3.11M 10-Q · filed 2022-10-28 | $4.86M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.08M 10-Q · filed 2022-08-04 | $3.83M derived: sum of 3 quarters · filed 2023-02-27 | $9.06M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.04M 10-Q · filed 2022-04-29 | $2.79M derived: sum of 2 quarters · filed 2023-02-27 | $8.02M derived: sum of 3 quarters · filed 2023-02-27 | $12.94M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $6.98M derived: sum of 2 quarters · filed 2023-02-27 | $11.89M derived: sum of 3 quarters · filed 2023-02-27 | $16.51M 10-K · filed 2023-02-27 |
| 2020-09-30 | $5.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $10.15M derived: sum of 2 quarters · filed 2021-10-29 | $14.77M 10-Q · filed 2021-10-29 | $19.33M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $4.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $9.53M 10-Q · filed 2021-07-30 | $14.10M derived: sum of 3 quarters · filed 2022-02-25 | $14.62M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $4.62M 10-Q · filed 2021-04-30 | $9.18M derived: sum of 2 quarters · filed 2022-02-25 | $9.71M derived: sum of 3 quarters · filed 2022-02-25 | $14.17M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $5.09M derived: sum of 2 quarters · filed 2022-02-25 | $9.55M derived: sum of 3 quarters · filed 2022-02-25 | $13.96M 10-K · filed 2022-02-25 |
| 2019-09-30 | $525.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $4.99M derived: sum of 2 quarters · filed 2020-11-06 | $9.39M 10-Q · filed 2020-11-06 | $14.48M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $8.87M 10-Q · filed 2020-08-05 | $13.96M derived: sum of 3 quarters · filed 2021-02-26 | $22.76M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $4.41M 10-Q · filed 2020-05-01 | $9.50M derived: sum of 2 quarters · filed 2021-02-26 | $18.30M derived: sum of 3 quarters · filed 2021-02-26 | $26.99M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $5.09M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $13.89M derived: sum of 2 quarters · filed 2021-02-26 | $22.59M derived: sum of 3 quarters · filed 2021-02-26 | $31.19M 10-K · filed 2021-02-26 |
| 2018-09-30 | $8.80M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $17.50M derived: sum of 2 quarters · filed 2019-11-04 | $26.10M 10-Q/A · filed 2019-11-04 | $34.61M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $8.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $17.30M 10-Q · filed 2019-08-02 | $25.81M derived: sum of 3 quarters · filed 2020-02-27 | $34.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $8.60M 10-Q · filed 2019-04-29 | $17.11M derived: sum of 2 quarters · filed 2020-02-27 | $25.30M derived: sum of 3 quarters · filed 2020-02-27 | $33.15M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $16.70M derived: sum of 2 quarters · filed 2020-02-27 | $24.55M derived: sum of 3 quarters · filed 2020-02-27 | $32.30M 10-K · filed 2020-02-27 |
| 2017-09-30 | $8.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $16.04M derived: sum of 2 quarters · filed 2018-10-26 | $23.79M 10-Q · filed 2018-10-26 | $31.45M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $7.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $15.60M 10-Q · filed 2018-08-03 | $23.25M derived: sum of 3 quarters · filed 2019-02-28 | $30.77M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $7.75M 10-Q · filed 2018-04-27 | $15.41M derived: sum of 2 quarters · filed 2019-02-28 | $22.92M derived: sum of 3 quarters · filed 2019-02-28 | $30.35M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $15.17M derived: sum of 2 quarters · filed 2019-02-28 | $22.59M derived: sum of 3 quarters · filed 2019-02-28 | $29.93M 10-K · filed 2019-02-28 |
| 2016-09-30 | $7.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $14.94M derived: sum of 2 quarters · filed 2017-10-31 | $22.28M 10-Q · filed 2017-10-31 | $29.53M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $7.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $14.76M 10-Q · filed 2017-08-02 | $22.01M derived: sum of 3 quarters · filed 2018-02-26 | $29.18M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $7.34M 10-Q · filed 2017-05-04 | $14.59M derived: sum of 2 quarters · filed 2018-02-26 | $21.75M derived: sum of 3 quarters · filed 2018-02-26 | |
| 2015-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $14.41M derived: sum of 2 quarters · filed 2018-02-26 | $28.49M 10-K · filed 2018-02-26 | |
| 2015-09-30 | $7.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $21.24M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $14.08M 10-Q · filed 2016-08-08 | |||
| 2014-12-31 | $27.23M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |